Skip to main content
. 2021 Jul 27;12:4536. doi: 10.1038/s41467-021-24769-3

Fig. 8. Predicted model of the NEK2–PD-L1 signaling pathway in pancreatic cancer.

Fig. 8

A schematic model is proposed to illustrate how PD-L1 protein stability is regulated by NEK2 in pancreatic cancer. NEK2 positively regulates and interacts with PD-L1 largely through PD-L1 phosphorylation at the T194/T210 residue in ER of pancreatic cancer. Therefore, treatment with NEK2 inhibitor unexpectedly suppressed PD-L1 protein expression, largely by inhibition of PD-L1 phosphorylation that promotes its degradation.